Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TPF + cetuximab
- Development stage
- Phase 3
- Lead developer
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
TPF + cetuximab is a multi-drug therapeutic regimen evaluated by the Grupo Español de Tratamiento de Tumores de Cabeza y Cuello (TTCC) for the treatment of resectable locally advanced laryngeal squamous cell carcinoma. The protocol consists of induction chemotherapy using the TPF triplet—docetaxel (a microtubule stabilizer), cisplatin (a DNA-damaging platinum agent), and fluorouracil (an antimetabolite that inhibits thymidylate synthase)—followed by radiotherapy administered concurrently with cetuximab. Cetuximab is a chimeric monoclonal antibody that targets the extracellular domain of the epidermal growth factor receptor (EGFR), which is frequently overexpressed in head and neck cancers. By blocking ligand binding, cetuximab inhibits downstream signaling pathways that promote tumor cell proliferation, survival, and angiogenesis. This sequential combination is designed to maximize tumor shrinkage and facilitate organ preservation, specifically aiming to improve laryngectomy-free survival in patients who would otherwise require radical surgery.
- Brand names
- ErbituxTaxoterePlatinolAdrucil
- Other names
- TPF-cetuximabDocetaxel + Cisplatin + Fluorouracil + Cetuximab
02
Targets
DNAEGFR (Epidermal growth factor receptor)TS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on TPF + cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TPF + cetuximab.